AHL
RYTM icon

Abel Hall LLC’s Rhythm Pharmaceuticals RYTM Stock Holding History

Abel Hall LLC’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$349K Buy
4,015
+1,875
+88% +$182K 0.07% 335
2025
Q4 		$229K Buy
+2,140
New +$227K 0.05% 472

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Abel Hall LLC's RYTM Position: Q1 2026 in Review

Abel Hall LLC increased its Rhythm Pharmaceuticals (RYTM) stake by 88% in Q1 2026, buying an estimated $182K and bringing the position to 4,015 shares worth $349K. The position accounts for 0.07% of the portfolio, ranked #335.

Abel Hall LLC first reported a position in RYTM in Q4 2025 and has held it in 2 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Abel Hall LLC held 4,015 shares of Rhythm Pharmaceuticals worth $349K as of Q1 2026.
  • Abel Hall LLC bought 1,875 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $182K.
  • Rhythm Pharmaceuticals made up 0.07% of Abel Hall LLC's portfolio in Q1 2026, its #335 holding.
  • Abel Hall LLC first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.